Cargando…

Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer

PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Cen, Bo, Wei, Jie, Wang, Dingzhi, Xiong, Ying, Shay, Jerry W., DuBois, Raymond N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526383/
https://www.ncbi.nlm.nih.gov/pubmed/34385594
http://dx.doi.org/10.1038/s41388-021-01972-6
Descripción
Sumario:PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the Adenomatous Polyposis Coli (APC) gene lead to colonic epithelial cell resistance to CD8(+) T cell cytotoxicity by induction of PD-L1 expression. Mechanistically this occurs as a result of the β-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway, but also pave the way for developing β-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.